CARTER-WALLACE FELBATOL DISCONTINUED USE RECOMMENDED DUE TO APLASTIC ANEMIA; FELBAMATE LOSS COULD MEAN THREE C-W Rx PRODUCTS OFF MARKET IN A YEAR